uniQure (NASDAQ:QURE – Free Report) – HC Wainwright decreased their FY2024 earnings per share estimates for uniQure in a report released on Monday, January 27th. HC Wainwright analyst P. Trucchio now anticipates that the biotechnology company will post earnings per share of ($4.17) for the year, down from their prior estimate of ($4.16). HC Wainwright currently has a “Buy” rating and a $70.00 target price on the stock. The consensus estimate for uniQure’s current full-year earnings is ($3.74) per share. HC Wainwright also issued estimates for uniQure’s Q4 2024 earnings at ($0.75) EPS, Q1 2025 earnings at ($0.66) EPS, Q2 2025 earnings at ($0.72) EPS, Q3 2025 earnings at ($0.75) EPS, Q4 2025 earnings at ($0.85) EPS, FY2025 earnings at ($2.99) EPS, FY2026 earnings at ($1.80) EPS, FY2027 earnings at $6.91 EPS and FY2028 earnings at $16.97 EPS.
QURE has been the subject of a number of other research reports. Royal Bank of Canada reissued an “outperform” rating and set a $24.00 price target on shares of uniQure in a research report on Tuesday, January 21st. Wells Fargo & Company raised uniQure from a “hold” rating to a “strong-buy” rating in a report on Tuesday, December 10th. Raymond James raised uniQure from an “outperform” rating to a “strong-buy” rating and upped their price target for the company from $20.00 to $52.00 in a research report on Tuesday, December 10th. Guggenheim reiterated a “buy” rating on shares of uniQure in a research note on Wednesday, December 11th. Finally, The Goldman Sachs Group lifted their target price on uniQure from $9.00 to $20.00 and gave the company a “neutral” rating in a research note on Thursday, December 12th. One analyst has rated the stock with a sell rating, two have issued a hold rating, six have given a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $40.00.
uniQure Stock Up 3.6 %
Shares of uniQure stock opened at $15.79 on Wednesday. The company has a debt-to-equity ratio of 0.92, a current ratio of 6.51 and a quick ratio of 6.51. uniQure has a 1-year low of $3.73 and a 1-year high of $19.18. The business has a 50-day moving average of $13.50 and a 200-day moving average of $8.88. The company has a market capitalization of $769.60 million, a PE ratio of -3.18 and a beta of 0.41.
uniQure (NASDAQ:QURE – Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($0.91) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.12) by $0.21. The company had revenue of $2.29 million for the quarter, compared to analyst estimates of $2.73 million. uniQure had a negative net margin of 837.80% and a negative return on equity of 188.82%.
Insider Activity at uniQure
In related news, CEO Matthew C. Kapusta sold 3,418 shares of the business’s stock in a transaction that occurred on Monday, December 9th. The stock was sold at an average price of $7.63, for a total transaction of $26,079.34. Following the sale, the chief executive officer now owns 597,915 shares of the company’s stock, valued at $4,562,091.45. The trade was a 0.57 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 4.74% of the company’s stock.
Hedge Funds Weigh In On uniQure
Institutional investors and hedge funds have recently added to or reduced their stakes in the company. RTW Investments LP acquired a new stake in shares of uniQure in the third quarter valued at $49,000. China Universal Asset Management Co. Ltd. lifted its holdings in uniQure by 57.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 10,093 shares of the biotechnology company’s stock valued at $50,000 after acquiring an additional 3,663 shares during the last quarter. Atria Investments Inc acquired a new stake in uniQure in the 3rd quarter valued at about $53,000. Quarry LP bought a new position in shares of uniQure during the 3rd quarter valued at about $58,000. Finally, Vanguard Personalized Indexing Management LLC grew its stake in shares of uniQure by 21.0% in the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 13,301 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 2,306 shares during the last quarter. 78.83% of the stock is owned by institutional investors.
uniQure Company Profile
uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.
Featured Stories
- Five stocks we like better than uniQure
- How to Short a Stock in 5 Easy Steps
- How Growth Investors Find High-Growth Stocks and Maximize Returns
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Meta’s AI & Smart Glasses Could Drive 20%+ Upside in 2025
- Market Cap Calculator: How to Calculate Market Cap
- NVIDIA’s Slide Continues: Can Retail Investors Stop the Fall?
Receive News & Ratings for uniQure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for uniQure and related companies with MarketBeat.com's FREE daily email newsletter.